Pancreatic Cancer Research

ResearcherUniversity of BonnActive in the last 2 years

Georg Feldmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3748-2184; OpenAlex author ID A5017611331. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers

Papers 16

  1. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer. Co-author DOI 10.3390/ijms25116249↗
  2. Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity … Co-author DOI 10.3390/jcm13133717↗
  3. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature. Co-author DOI 10.21037/jgo-22-632↗
  4. [Medicinal treatment of pancreatic cancer : Still a domain of chemotherapy?] Co-author DOI 10.1007/s00108-020-00750-y↗
  5. Animal models for modeling pancreatic cancer and novel drug discovery. First author DOI 10.1080/17460441.2019.1566319↗
  6. 'Diseases Desperate Grown by Desperate Appliance Are Relieved, or Not at all' - Towards Finding a Cure for Pancreatic Cancer, Where Do We Stand Today? Co-author DOI 10.1159/000493023↗
  7. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1159/000493401↗
  8. Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts. First author DOI 10.1159/000493437↗
  9. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1159/000493868↗
  10. Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. Co-author DOI 10.1186/s12885-017-3225-5↗
  11. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. Last author DOI 10.1186/s12951-016-0209-6↗
  12. The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. Co-author DOI 10.18632/oncotarget.8437↗
  13. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. Co-author DOI 10.1074/jbc.m112.405837↗
  14. Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. Last author DOI 10.1517/17460441.2011.534453↗
  15. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Co-author DOI 10.4161/cbt.11.11.15534↗
  16. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Co-author DOI 10.4161/cbt.12.7.16475↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Savita Bisht · 9 shared papers, 2011–2024 · strength 0.95
  2. Tim R. Glowka · 2 shared papers, 2023–2024 · strength 0.32
  3. Christian Möhring · 2 shared papers, 2023–2024 · strength 0.32
  4. Milka Marinova · 2 shared papers, 2023–2024 · strength 0.32
  5. Maria Angeles Gonzalez-Carmona · 2 shared papers, 2023–2024 · strength 0.32
  6. Xuan Wang · 1 shared paper, 2024 · strength 0.24
  7. Anirban Maitra · 3 shared papers, 2011–2018 · strength 0.18
  8. Ingo G.H. Schmidt‐Wolf · 1 shared paper, 2024 · strength 0.15
  9. Marcus O. Thudium · 1 shared paper, 2024 · strength 0.15
  10. Holger M. Strunk · 1 shared paper, 2024 · strength 0.15
  11. Anna Schmitt · 1 shared paper, 2018 · strength 0.12
  12. Hans Christian Reinhardt · 1 shared paper, 2018 · strength 0.12
  13. Alessio Nencioni · 2 shared papers, 2012–2016 · strength 0.08
  14. Inga Bauer · 2 shared papers, 2012–2016 · strength 0.08
  15. Nuh N. Rahbari · 1 shared paper, 2017 · strength 0.06
  16. Mathieu Pecqueux · 1 shared paper, 2017 · strength 0.06
  17. Bianca T. Hofmann · 1 shared paper, 2017 · strength 0.06
  18. Tristan Lerbs · 1 shared paper, 2017 · strength 0.06
  19. Christoph Reißfelder · 1 shared paper, 2017 · strength 0.06
  20. Sebastian Schölch · 1 shared paper, 2017 · strength 0.06
  21. Thilo Welsch · 1 shared paper, 2017 · strength 0.06
  22. Christoph Kahlert · 1 shared paper, 2017 · strength 0.06
  23. Jürgen Weitz · 1 shared paper, 2017 · strength 0.06
  24. Martin Schlesinger · 1 shared paper, 2016 · strength 0.06
  25. Stefan Holdenrieder · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.